Trial reportCirculation2007
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Trial report in Circulation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Obesity in adults.BMJ clinical evidence · 2011Pooled it
- Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial.Hypertension (Dallas, Tex. : 1979) · 2010Trial
- Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Review
- Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?European archives of psychiatry and clinical neuroscience · 2015Review
- Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk.Journal of the National Cancer Institute · 2014Article
- Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study.American journal of cardiovascular disease · 2011Article
- Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model.BMC public health · 2010Article
- Drug mechanisms to help in managing resistant hypertension in obesity.Current hypertension reports · 2010Review
- Epithelial Na+ channel (ENaC), hormones, and hypertension.The Journal of biological chemistry · 2010Review
- Tackling obesity: new therapeutic agents for assisted weight loss.Diabetes, metabolic syndrome and obesity : targets and therapy · 2010Article
- The use of sibutramine in the management of obesity and related disorders: an update.Vascular health and risk management · 2009Review
- Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care.BMC cardiovascular disorders · 2008Article
- Management of obesity in the elderly: too much and too late?The journal of nutrition, health & aging · 2008Review
- Hypertension with metabolic syndrome: think thiazides are old hat? ALLHAT says think again.The Journal of family practice · 2008Article
- Treatment strategies for obesity-related hypertension.Current hypertension reports · 2008Article
- The clinical significance of metabolic syndrome in hypertension: metabolic syndrome increases cardiovascular risk : the pro position.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2008Article
- Local adipose tissue renin-angiotensin system.Current hypertension reports · 2008Review
- The treatment of hypertension in obese patients.Current hypertension reports · 2008Review
- Does it matter how we lower blood pressure in obese hypertensive patients?Current hypertension reports · 2008Article
- Management of arterial hypertension in obese patients.Current hypertension reports · 2007Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients. To identify an optimal treatment regimen for obese hypertensive patients, we studied the interactions between a drug-based weight loss approach by sibutramine and different antihypertensive drug regimens. METHODS AND
resultsThis was a prospective, 16-week double-blind placebo-controlled randomized multicenter study in 171 obese hypertensive patients. After a 2-week run-in period, patients receiving 1 of the 3 antihypertensive combination therapies (felodipine 5 mg/ramipril 5 mg [n=57], verapamil 180 mg/trandolapril 2 mg [n=55], or metoprolol succinate 95 mg/hydrochlorothiazide 12.5 mg [metoprolol/hydrochlorothiazide; n=59]) were assigned randomly to sibutramine (15 mg) or placebo. Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment. Sibutramine-induced weight loss and reduction of visceral obesity were markedly attenuated in the metoprolol/hydrochlorothiazide group compared with the other groups. Consistently, improvement in glucose tolerance and hypertriglyceridemia by sibutramine was abrogated in the cohort treated with metoprolol/hydrochlorothiazide compared with the other groups.
conclusionsThe present study demonstrates for the first time that an antihypertensive combination therapy regimen with angiotensin-converting enzyme inhibitors and calcium channel blockers is more advantageous than a beta-blocker/diuretic-based regimen in supporting the weight-reducing actions and concomitant metabolic changes induced by sibutramine in obese hypertensive patients. These data may help to develop future comprehensive treatment strategies and guidelines for this high-risk patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.